Vial Filling
Catalent Biologics’ automated vial filling at its Anagni, Italy, Bloomington, Indiana, and Limoges, France sites have the ability to provide billions of doses for your patients, including sterile and …
Showing Results 81-90 Of 76 For Italy
Catalent Launches OptiGel® DR, a Delayed/Enteric Release Softgel for Pharmaceutical and Nutraceutical Applications
Catalent today announced the launch of OptiGel® DR technology for the formulation and manufacture of delayed/enteric release softgels. The technology allows softgel capsules to be formed by combining pectin, a naturally derived polysaccharide, with gelatin, eliminating the need for a separate capsule coating step.
Novo Holdings Completes Acquisition of Catalent
Catalent and Novo Holdings today announced that Novo Holdings has completed its previously announced acquisition of Catalent in an all-cash transaction with a total enterprise value of approximately $16.5 billion.
Catalent Biologics Supports DiaMedica’s New Treatment for Chronic Kidney Disease
Catalent today welcomed the news that DiaMedica Therapeutics has received U.S. FDA approval to commence Phase 2 clinical trials of its lead candidate, DM199, for chronic kidney disease.
Catalent Biologics Completes $14 Million Commercial Packaging Expansion at its Bloomington, Indiana Facility
Catalent today announced the completion of its $14 million expansion to increase the biologics packaging capabilities and capacity at its Bloomington, Indiana facility.